May 1, 2026FDA Moves to Remove GLP-1 Weight Loss Drugs from Compounding ListFDA announced plans to exclude semaglutide, tirzepatide, and liraglutide from its 503B compounding list, citing no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.May 1, 2026·1 source00
Apr 18, 2026Weight Loss Medications Lead to Notable Muscle Loss Alongside Fat LossUNC School of Medicine study finds incretin-based medications including semaglutide and tirzepatide cause significant muscle loss in addition to fat reduction, raising concerns about long-term metabolic effects.Apr 18, 2026·1 source00
Apr 10, 2026AI Analysis of 400,000 Reddit Posts Identifies Overlooked GLP-1 Drug Side EffectsUniversity of Pennsylvania researchers used AI to analyze over 400,000 Reddit posts to identify patient-reported symptoms associated with semaglutide and tirzepatide that may not be captured in clinical trials.Apr 10, 2026·1 source00
